| Symbol | HXBM |
|---|---|
| Name | HELIX BIOMEDIX, INC. |
| Sector | UNDEFINED |
| Region | North America |
| Industry | - |
| Address | 98041 United States WA PO Box 1748 |
| Telephone | +1 425-402-8400 |
| Fax | — |
| — | |
| Website | http://www.helixbiomedix.com |
| Incorporation | US |
| Incorporated On | 2000 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC |
| Auditor | Moss Adams LLP; |
| Audit Status | UNAUDITED |
| Reporting Status | Alternative Reporting Standard |
| CIK | 0000831749 |
| Description | Helix BioMedix is a preclinical biopharmaceutical company focused on drug development for treatment of rare dermatological diseases, such as xeroderma pigmentosum. Our legacy R&D consists of an extensive proprietary library of patented bioactive peptides based on the bodys innate immunity many of which the company has outlicensed to partners to commercialize. Helix BioMedix, Inc., is committed to building long term shareholder value through development of novel drugs for rare dermatological conditions with unmet needs and strategic management of our diverse peptide library. Additional info from OTC: |
No news found.